---
title: "Lysergide (DT120) in Generalized anxiety disorder: Second-generation antipsychotics"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Second-generation antipsychotics. Topics: FDA-approved indications of quetiapine extended release, CANMAT guideline: quetiapine XR as second-line monotherapy, CANMAT guideline: adjunctive antipsychotics as third-line therapy, NICE guideline: antipsychotics in primary care, and 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/second-generation-antipsychotics"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Second-generation antipsychotics

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Second-generation Antipsychotics

<a id="topic-2.2.2.1.8-1"></a>

### FDA-approved indications of quetiapine extended release

> “SEROQUEL XR is an atypical antipsychotic indicated for the treatment of:”
> “SEROQUEL XR is indicated for the treatment of schizophrenia.”
> “SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex.”
> “SEROQUEL XR is indicated for the acute treatment of depressive episodes associated with bipolar disorder.”
> “SEROQUEL XR is indicated for use as adjunctive therapy to antidepressants for the treatment of MDD.”

Source: [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)

<a id="topic-2.2.2.1.8-2"></a>

### CANMAT guideline: quetiapine XR as second-line monotherapy

> “Quetiapine XR: There is good evidence for the efficacy of quetiapine XR for the management of GAD (Level 1)”
> “However, quetiapine was associated with more weight gain and sedation, and higher dropout rates due to adverse events compared with placebo or antidepressants”
> “Due to tolerability and long-term safety concerns with atypical antipsychotics, this treatment is recommended as a second-line option for patients who cannot be provided antidepressants or benzodiazepines.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.8-3"></a>

### CANMAT guideline: adjunctive antipsychotics as third-line therapy

> “Third-line adjunctive therapies: A meta-analysis of five RCTs of adjunctive atypical antipsychotics found no significant improvement in response rates but higher discontinuation rates versus placebo in patients with refractory GAD”
> “Because of the limited evidence for efficacy and their potential for weight gain and metabolic side effects, atypical antipsychotics should be reserved for highly treatment-refractory cases of GAD, and other than quetiapine XR, used only as an adjunctive treatment.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.8-4"></a>

### NICE guideline: antipsychotics in primary care

> “Do not offer an antipsychotic for the treatment of GAD in primary care.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.8-5"></a>

### BAP guideline: reserved for nonresponse to other interventions

> “The tolerability profile of antipsychotic drugs is such that they should generally be reserved for treatment after a non-response to other interventions”
> “but the evidence for quetiapine augmentation is inconsistent”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.8-6"></a>

### AAFP review: effectiveness and augmentation

> “Limited evidence suggests that antipsychotics have poor effectiveness and cause several adverse effects.”
> “There is no evidence of overall benefit to augmentation of antidepressant therapy with benzodiazepines, atypical antipsychotics, or buspirone (Buspar) in treatment-resistant anxiety disorders.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.8-7"></a>

### Meta-analysis of quetiapine randomized trials

> “A total of 2,248 randomized participants in three RCTs were included.”
> “Unfortunately, the response and the remission rates in only 50 and 150 mg/day of quetiapine-XR (extended-release) were better than those of the placebo.”
> “The rates of pooled overall discontinuation and discontinuation due to adverse events of quetiapine-XR were greater than placebo.”
> “Based on the pooled discontinuation rate due to adverse events of the quetiapine-treated group being significantly higher than that of the placebo-treated group, with RR (95% CI) of 3.18 (2.52, 4.00), I2=0%, it suggests that quetiapine is less tolerable than placebo in the treatment of GAD”
> “Based on the evidence included in this meta-analysis, the significant adverse events consist of somnolence, sexual dysfunction, and extrapyramidal symptoms.”

Source: [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/)

<a id="topic-2.2.2.1.8-8"></a>

### Network meta-analysis: effect size and tolerability of quetiapine

> “Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.8-9"></a>

### Fixed-dose trial of quetiapine XR

> “Among patients randomized to fixed-dose treatment (quetiapine XR: 50 mg/day, n=234; 150 mg/d, n=241; 300 mg/d, n=241) or placebo (n=235) quetiapine was statistically superior to placebo except at the 300 mg/day dose, wherein side effects were significantly greater”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
